Firefly Neuroscience Inc Dossier
Qualitative Analysis
Business overview
Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an artificial intelligence medical technology company advancing precision neuroscience. The company applies AI and large-scale electrophysiological data to provide clinicians with a complete, objective picture of brain function. Its core offering is the FDA 510(k)-cleared Brain Network Analytics (BNA) software platform, which is designed to improve outcomes for patients suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety, concussions, and ADHD. Firefly's proprietary database underpins its technology, containing over 191,000 EEG and ERP recordings. The company operates primarily in North America and generates revenue through equipment sales, rentals, per-use fees, and subscription/lease models.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building the world's first proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology platform, leveraging Resting EEG and Cognitive EEG (ERP) data.
Expected impact: Aims to revolutionize precision neuroscience, enabling high-throughput biomarker discovery and advanced diagnostic capabilities.
Transitioning the acquired Evoke System from one-time product sales to a subscription/lease model to increase recurring revenue focus.
Expected impact: Establishes a predictable, high-margin recurring revenue stream tied directly to assessment scan volumes.
Deploying the next-generation CLEAR (CLeaning EEG ARtifacts) preprocessing platform running on NVIDIA L40S GPU-accelerated infrastructure to strip out interference while preserving clinically relevant brain signals.
Expected impact: Reduces data processing times by 60% to 80% and substantially increases data quality for biomarker research.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand Firefly's standardized EEG/ERP database, increase granted patents, grow the commercial user base, and accelerate the development of its AI-driven brain health platform.
Financial impact: Drove a 957% year-over-year revenue increase in fiscal 2025 to $1.142 million and expanded the commercial footprint over 20-fold.
Strategic Partnerships
Supports the assessment and treatment of active-duty U.S. service members and veterans suffering from PTSD and/or Traumatic Brain Injury (TBI) using Firefly's FDA-cleared EEG/ERP technology.
Terms: Specific financial details remain confidential.
Collaborating with the Institute of Human Genetics to study the neurophysiological effects of 15q13.3 copy number variants (CNVs) using Firefly's BNA technology.
Terms: Firefly is providing EEG systems, training, and analytical support.
Offering cognitive electrophysiology analytics to over 2,500 ketamine, psilocybin, and TMS clinics across North America.
Terms: Commercial agreement to expand the clinical footprint of the BNA platform.